| 001 | 137550 | ||
| 005 | 20210129212048.0 | ||
| 024 | 7 | _ | |a 10.2967/jnumed.113.120089 |2 doi |
| 024 | 7 | _ | |a pmid:23785172 |2 pmid |
| 024 | 7 | _ | |a 0097-9058 |2 ISSN |
| 024 | 7 | _ | |a 0161-5505 |2 ISSN |
| 024 | 7 | _ | |a 1535-5667 |2 ISSN |
| 024 | 7 | _ | |a 0022-3123 |2 ISSN |
| 024 | 7 | _ | |a WOS:000322692400026 |2 WOS |
| 024 | 7 | _ | |a altmetric:1574500 |2 altmetric |
| 037 | _ | _ | |a FZJ-2013-03983 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Heinzel, A. |0 P:(DE-Juel1)132315 |b 0 |u fzj |e Corresponding author |
| 245 | _ | _ | |a The Use of O-(2-18F-Fluoroethyl)-L-Tyrosine PET for Treatment Management of Bevacizumab and Irinotecan in Patients with Recurrent High-Grade Glioma: A Cost-Effectiveness Analysis. |
| 260 | _ | _ | |a Reston, Va. |c 2013 |b SNM84042 |
| 264 | _ | 1 | |3 online |2 Crossref |b Society of Nuclear Medicine |c 2013-06-19 |
| 264 | _ | 1 | |3 print |2 Crossref |b Society of Nuclear Medicine |c 2013-08-01 |
| 264 | _ | 1 | |3 print |2 Crossref |b Society of Nuclear Medicine |c 2013-08-01 |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1378130902_18088 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 500 | _ | _ | |3 POF3_Assignment on 2016-02-29 |
| 520 | _ | _ | |a To date, the use of structural MR imaging (including contrast-enhanced and T2-weighted or fluid-attenuated inversion recovery-weighted images) is the standard method to diagnose tumor progression and to assess antiangiogenic treatment effects. However, several studies have suggested that O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET) PET adds valuable clinical information to the information derived from structural MR imaging alone. We evaluated the effectiveness and cost-effectiveness of the addition of (18)F-FET PET to structural MR imaging for the management of treatment with bevacizumab and irinotecan (BEV/IR) in patients with recurrent high-grade glioma compared with MR imaging alone from the perspective of the German Statutory Health Insurance.To evaluate the incremental cost-effectiveness of the additional use of (18)F-FET PET, a decision tree model was used. Effectiveness of (18)F-FET PET was defined as correct identification of both tumor progression before BEV/IR treatment initiation and BEV/IR treatment response and was evaluated for the combination of (18)F-FET PET and MR imaging compared with MR imaging alone. Costs were estimated for a baseline scenario and for a more expensive scenario. The robustness of the results was tested using deterministic and probabilistic sensitivity analyses.The use of (18)F-FET PET resulted in a number needed to diagnose of 2.4, that is, 3 additional patients have to be diagnosed to avoid 1 wrong diagnosis. The incremental cost-effectiveness ratio of (18)F-FET PET/MR imaging compared with MR imaging alone was €5,725 (€1 ≈ $1.30) for the baseline scenario and €8,145 for the more expensive scenario per additional correct diagnosis. The probabilistic sensitivity analysis confirmed the robustness of the results.The model suggests that the additional use of (18)F-FET PET in the management of patients with recurrent high-grade glioma treated with BEV/IR may be cost-effective. Integration of (18)F-FET PET has the potential to avoid overtreatment and corresponding costs, as well as unnecessary side effects to the patient. |
| 536 | _ | _ | |a 332 - Imaging the Living Brain (POF2-332) |0 G:(DE-HGF)POF2-332 |c POF2-332 |x 0 |f POF II |
| 588 | _ | _ | |a Dataset connected to CrossRef, juser.fz-juelich.de, PubMed, |
| 700 | 1 | _ | |a Müller, Dirk |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 2 |u fzj |
| 700 | 1 | _ | |a Blaum, Marcus |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Verburg, Frederik Anton |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Mottaghy, Felix M |0 P:(DE-Juel1)132318 |b 5 |u fzj |
| 700 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 6 |u fzj |
| 773 | 1 | 8 | |a 10.2967/jnumed.113.120089 |b : Society of Nuclear Medicine, 2013-06-19 |n 8 |p 1217-1222 |3 journal-article |2 Crossref |t Journal of Nuclear Medicine |v 54 |y 2013 |x 0161-5505 |
| 773 | _ | _ | |a 10.2967/jnumed.113.120089 |g Vol. 54, no. 8, p. 1217 - 1222 |p 1217-1222 |n 8 |0 PERI:(DE-600)2040222-3 |t Journal of nuclear medicine |v 54 |y 2013 |x 0161-5505 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/137550/files/FZJ-2013-03983.pdf |z Published final document. |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:137550 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)132315 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)131777 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)132318 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)143792 |
| 913 | 2 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-579H |2 G:(DE-HGF)POF3-500 |v Addenda |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Funktion und Dysfunktion des Nervensystems |1 G:(DE-HGF)POF2-330 |0 G:(DE-HGF)POF2-332 |2 G:(DE-HGF)POF2-300 |v Imaging the Living Brain |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF2 |
| 914 | 1 | _ | |y 2013 |
| 915 | _ | _ | |a JCR/ISI refereed |0 StatID:(DE-HGF)0010 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 981 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::